🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Guangzhou Lupeng Pharmaceutical Company clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Guangzhou Lupeng Pharmaceutical Company as lead sponsor. Synced 26 Sep 2026
12Current trials
9Recruiting now
14Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Guangzhou Lupeng Pharmaceutical Company is the lead sponsor of 12 current clinical trials in our China register. 9 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Rocbrutinib, Lacutoclax and Rituximab. The most-studied condition is Mantle Cell Lymphoma (MCL).

ClinicalTrials.gov trials by status

  • Recruiting975%
  • Active, closed325%

Trials by phase

  • Phase 1650%
  • Phase 2433%
  • Phase 318%
  • Phase 1/218%
01

Clinical trials sponsored by Guangzhou Lupeng Pharmaceutical Company

12 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT07570017 · ClinicalTrials.gov ↗ · DLBCL
Phase 1 Recruiting 2026-06 China
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
NCT04993690 · ClinicalTrials.gov ↗ · B-cell Lymphoma
Phase 1 Recruiting 2021-07 China
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
NCT07776743 · ClinicalTrials.gov ↗ · Relapsing-remitting Multiple Sclerosis (RRMS)
Phase 2 Recruiting 2026-08 China
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT07377578 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma
Phase 3 Recruiting 2026-02 China
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2 Recruiting 2025-11 China
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
NCT05641259 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Phase 1 Recruiting 2023-02 China
A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
NCT07609823 · ClinicalTrials.gov ↗ · Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Recruiting 2026-07 China
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
NCT07609862 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL)
Phase 1/2 Recruiting 2026-07 China
A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet
NCT07374224 · ClinicalTrials.gov ↗ · Clinical Pharmacology
Phase 1 Recruiting 2026-03 China
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
NCT05716087 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma (MCL)
Phase 2 Active, closed 2023-02 China
A Study of LP-128 Capsules in Healthy Subjects
NCT05130567 · ClinicalTrials.gov ↗ · Chronic Hepatitis b
Phase 1 Active, closed 2021-11 China
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma
NCT06251180 · ClinicalTrials.gov ↗ · B-cell Non-Hodgkin Lymphoma
Phase 1 Active, closed 2024-04 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Guangzhou Lupeng Pharmaceutical Company trials

14 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Guangzhou Lupeng Pharmaceutical Company trials

15 conditions
Mantle Cell Lymphoma (MCL)2Diffuse Large B-Cell Lymphoma (DLBCL)2DLBCL1Chronic Hepatitis b1B-cell Lymphoma1Relapsing-remitting Multiple Sclerosis (RRMS)1Mantle Cell Lymphoma1B-cell Non-Hodgkin Lymphoma1Acute Myeloid Leukemia1Myelodysplastic Syndromes1Chronic Myelomonocytic Leukemia1Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma1Follicular Lymphoma ( FL)1Waldenström Macroglobulinemia (WM)1Clinical Pharmacology1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China129

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Mantle Cell Lymphoma (MCL)

SponsorTrials
Acerta Pharma2

Sponsors with the most current trials registered for this condition.

06

Questions about Guangzhou Lupeng Pharmaceutical Company trials

How many clinical trials does Guangzhou Lupeng Pharmaceutical Company sponsor?

Guangzhou Lupeng Pharmaceutical Company is the lead sponsor of 12 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Guangzhou Lupeng Pharmaceutical Company trials recruiting?

Yes. 9 of its 12 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Guangzhou Lupeng Pharmaceutical Company testing?

Its current trials name 14 drugs and biologicals as interventions. The most frequent are Rocbrutinib (6), Lacutoclax (2), Rituximab (2), Adriamycin (1) and Azacitidine (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.